Its efficacy and safety were also tested in combination with ruxolitinib and a remission rate of 31% for PV patients and 44% for MF patients was observed, resulting in both JAK2 V617F allele burden decreasing and a reduction in inflammation [45]. Here, JAK2 is linked to acquired polycythemia vera.